

SNLong Term Care Facility Component—Annual Facility Survey

, L À	NELWOIK			
	Page	1	of	6

Instructions for this form can be accessed: https://www.cdc.gu	ov/nhsn/forms/instr/57.137-to	<u>pi-annual-facility-survey.pdf</u>
*Required for saving	Tracking #:	
Facility ID:	*Survey Year:	
*National Provider ID:	State Provider #:	
Facility Characteristics		
*Ownership (check one):		
□ For profit □ Not for profit, including church	Government (not VA)	□ Veterans Affairs
*Certification (check one):		
Dual Medicare/Medicaid Medicare only	Medicaid only	\Box State only
*Affiliation (check one):	Independent, continuin community	g care retirement
	i, attached 🛛 Hospital syst	tem, free-standing
In the previous calendar year: *Average daily census:		
Average daily census.		
	ge length of stay for short-sta	
*Total number of long-stay residents: Avera	ge length of stay for long-stay	y residents:
*Total number of new admissions:		
*Number of Beds: *Number of Pediatric Be	ds (age <21):	
*Indicate which of the following primary service types are pro-		
the number of residents receiving those services (list only on	e service type per resident, i.	e. total should sum to
resident census on day of survey completion):		ar of regidente
	· · · · · · · · · · · · · · · · · · ·	er of residents
a. Long-term general nursing:	L	
b. Long-term dementia:		
c. Skilled nursing/Short-term (subacute) rehabilitation:		
d. Long-term psychiatric (non-dementia):		
e. Ventilator:		
f. Bariatric:	□ <u> </u>	
g. Hospice/Palliative:		
h. Other:		

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 2 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666).

CDC 57.137 (Front) Rev EOY Release?

Continued >>



Facility Microbiology Laboratory	/ Practices			
*1. Does your facility have its own		microbiology/anti	microbial susceptibility testing?	
🗆 Yes 🛛 No				
If No, where is your facility's	s antimicrobial susceptib	ility testing perforr	ned? (check one)	
□ Affiliated med	ical center, within same	health system	🗌 Medical center, contracte	ed locally
Commercial re	eferral laboratory			
*2. Indicate whether your facility so (MDROs): (check all that apply		or any of the follow	ving multidrug-resistant organis	ms
\Box We do not screen new a	dmissions for MDROs			
Methicillin-resistant Stap If checked, indicate the	hylococcus aureus (MR: specimen types sent fo		< all that apply)	
🗌 Nasal swabs	\Box Wound swabs	Sputum	\Box Other skin site	
U Vancomycin-resistant Er	nterococcus (VRE)			
-	specimen types sent fo	screening: (chec	c all that apply)	
\Box Rectal swabs	\Box Wound swabs	🗌 Urine		
resistant Acinetobacter, e	• •	·	esistant Enterobacteriaceae; mi < all that apply)	ultidrug-
\Box Rectal swabs	\Box Wound swabs	Sputum	Urine	
🗌 Candida Auris (C.Auris)				
	specimen types sent fo			
	specimen types sent fo			
If checked, indicate the Skin (axilla/groin)	thod for <i>C. difficile</i> used	r screening: (chec Nares most often by you	< all that apply)	 de labora
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met	thod for <i>C. difficile</i> used performed? (check one)	r screening: (chec Nares most often by you	< all that apply)	 de laborat
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is	thod for <i>C. difficile</i> used performed? (check one) A) for toxin	n screening: (chec Nares most often by you GDH plu GDH plu	< all that apply)	
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is Enzyme immunoassay (EL	thod for <i>C. difficile</i> used performed? (check one) A) for toxin tion assay	r screening: (chec Nares most often by you GDH plu GDH plu discrepa	< all that apply) Other site facility's laboratory or the outsi s NAAT (2-step algorithm) s EIA for toxin, followed by NAA	T for
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is Enzyme immunoassay (EI Cell cytotoxicity neutralizat	thod for <i>C. difficile</i> used performed? (check one) A) for toxin tion assay test (NAAT) (e.g., PCR,	r screening: (chec Nares most often by you GDH plu discrepa Culture (toxins)	k all that apply) Other site facility's laboratory or the outsi s NAAT (2-step algorithm) s EIA for toxin, followed by NAA int results	T for etection o
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is Enzyme immunoassay (El Cell cytotoxicity neutralizat Nucleic acid amplification t LAMP)	thod for <i>C. difficile</i> used performed? (check one) A) for toxin tion assay test (NAAT) (e.g., PCR, positive (2-step algorithm)	r screening: (chec Nares most often by you GDH plu GDH plu discrepa Culture (toxins)	all that apply) Conter site facility's laboratory or the outsi S NAAT (2-step algorithm) S EIA for toxin, followed by NAA ant results <i>C. difficile</i> culture followed by de	T for etection o
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is Enzyme immunoassay (EI Cell cytotoxicity neutralizat Cell cytotoxicity neutralizat Nucleic acid amplification t LAMP) NAAT plus EIA, if NAAT po Glutamate dehydrogenase toxin (2-step algorithm) ("Other" should not be used to name s	thod for <i>C. difficile</i> used performed? (check one) A) for toxin tion assay test (NAAT) (e.g., PCR, ositive (2-step algorithm) e (GDH) antigen plus EIA specific laboratories, referen by by selecting from the opt	r screening: (chec Nares most often by you GDH plu GDH plu discrepa Culture (toxins) Other (sp for nce laboratories, or for	A all that apply) C Other site T facility's laboratory or the outsi S NAAT (2-step algorithm) S EIA for toxin, followed by NAA ant results C. difficile culture followed by de Decify):	T for etection o
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is Enzyme immunoassay (EL Cell cytotoxicity neutralizat Cell cytotoxicity neutralizat Nucleic acid amplification t LAMP) NAAT plus EIA, if NAAT po Glutamate dehydrogenase toxin (2-step algorithm) ("Other" should not be used to name s methods can be categorized accurated Instructions for this form, or conduct a	thod for <i>C. difficile</i> used performed? (check one) A) for toxin tion assay test (NAAT) (e.g., PCR, ositive (2-step algorithm) e (GDH) antigen plus EIA specific laboratories, referen by by selecting from the opt search for further guidance report summarizing the	r screening: (chec Nares Most often by you GDH plu GDH plu discrepa Culture (toxins) Other (st for nce laboratories, or to ions provided. Plea e on selecting the co percent of antibio	A all that apply) C Other site T facility's laboratory or the outsi S NAAT (2-step algorithm) S EIA for toxin, followed by NAA ant results C. difficile culture followed by de Decify): he brand names of C. difficile tests as ask your laboratory, refer to the rrect option to report.)	AT for etection or ; most Tables of
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is Enzyme immunoassay (EI Cell cytotoxicity neutralizat Cell cytotoxicity neutralizat Nucleic acid amplification t LAMP) NAAT plus EIA, if NAAT po Glutamate dehydrogenase toxin (2-step algorithm) ("Other" should not be used to name s methods can be categorized accurated Instructions for this form, or conduct a	thod for <i>C. difficile</i> used performed? (check one) A) for toxin tion assay test (NAAT) (e.g., PCR, ositive (2-step algorithm) e (GDH) antigen plus EIA specific laboratories, referen by by selecting from the opt search for further guidance report summarizing the	r screening: (chec Nares Most often by you GDH plu GDH plu discrepa Culture (toxins) Other (st for nce laboratories, or to ions provided. Plea e on selecting the co percent of antibio	A all that apply) C Other site T facility's laboratory or the outsi S NAAT (2-step algorithm) S EIA for toxin, followed by NAA ant results C. difficile culture followed by de Decify): he brand names of C. difficile tests as ask your laboratory, refer to the rrect option to report.)	AT for etection or ; most Tables of
If checked, indicate the Skin (axilla/groin) *3. What is the primary testing met where your facility's testing is Enzyme immunoassay (EI Cell cytotoxicity neutralizat Cell cytotoxicity neutralizat Nucleic acid amplification t LAMP) NAAT plus EIA, if NAAT po Glutamate dehydrogenase toxin (2-step algorithm) ("Other" should not be used to name s methods can be categorized accurated Instructions for this form, or conduct a *4. Does your laboratory provide a identified in cultures sent from	thod for <i>C. difficile</i> used performed? (check one) A) for toxin tion assay test (NAAT) (e.g., PCR, ositive (2-step algorithm) e (GDH) antigen plus EIA specific laboratories, referen by selecting from the opt search for further guidance report summarizing the your facility (often called	r screening: (chec Nares Most often by you GDH plu GDH plu discrepa Culture (toxins) Other (si for nce laboratories, or to ions provided. Plea e on selecting the co percent of antibio I an antibiogram)?	A all that apply) Other site facility's laboratory or the outsi s NAAT (2-step algorithm) s EIA for toxin, followed by NAA ant results <i>C. difficile</i> culture followed by de becify): becify): becify): c ask your laboratory, refer to the formation of <i>C. difficile</i> tests c ask your laboratory, refer to the formation of the provide the provided of the	T for etection of ; most Tables of



Infect	on Prevention and Control Practices
*5. To	al staff hours per week dedicated to infection prevention and control activity in facility:
a. 1	otal hours per week performing surveillance:
b. 1	otal hours per week for infection prevention and control activities other than surveillance:
	a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with RSA? (Check one)
	Yes, all infected and colonized residents with MRSA
	Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence an indwelling device)
	l No
	a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with E? (Check one)
	Yes, all infected and colonized residents with VRE
	Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device)
	Νο
	a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with E? (Check one)
	Yes, all infected and colonized residents with CRE
	Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence an indwelling device)
	Νο
	a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with BL-producing or extended spectrum cephalosporin resistant Enterobacteriaceae? (Check one)
	Yes, all infected and colonized residents with ESBL
	Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence an indwelling device)
	l No
	hen a resident colonized or infected with an MDRO is transferred to another facility, does ur facility communicate the resident's MDRO status to the receiving facility at the time of Yes No
	nsfer?



People are f 6			
Infection Prevention and Control Practices (continued)			
*11. Among residents with an MDRO admitted to your facil percentage of the time does your facility receive inform resident's MDRO status?		he	%
Antibiotic Stewardship Practices			
*12. Are there one or more individuals responsible for the i antimicrobials at your facility?	mpact of activities to improve use of	□ Yes	🗆 No
If Yes, what is the position of the individual(s)? (se	lect all that apply)		
□ Medical director □ Director of Nu	rsing 🛛 Infection Preventior	list	
\Box Consultant Pharmacist \Box Other (please	specify):		
*13. Does your facility have a policy that requires prescribe antimicrobials in the medical record or during order er		□ Yes	🗌 No
If Yes, has adherence to the policy to document ar	n indication been monitored?	□ Yes	🗌 No
*14.Does your facility provide treatment recommendations national guidelines to assist with antimicrobial decision		□ Yes	🗆 No
If Yes, has adherence to facility-specific treatment	recommendations been monitored?	🗌 Yes	🗆 No
*15. Is there a formal procedure for performing a follow-up antimicrobial start to determine whether the antimicrol (e.g. antibiotic time out)?		□ Yes	🗌 No
*16. Is there a formal procedure for reviewing courses of a with prescribers on antimicrobial selection, dosing, or feedback) at your facility?		□ Yes	□ No
*17.Does your facility have a system for tracking antimicrol If yes, what is the source of the antimicrobial use r		□ Yes	□ No
Pharmacy services	Electronic Health Records		
☐ Manual reporting (i.e., facility infection control log)	□ Other (please specify):		
*18. Has your facility provided education to clinicians and c antimicrobial use in the past 12 months?	other facility staff on improving	□ Yes	🗆 No
*19. Does your facility have a written statement of support improve antimicrobial use?	from leadership that supports efforts to	□ Yes	🗆 No
		Con	ntinued >>

Long Term Care Facility Component—Annual Facility Survey



Antibiotic Stewardship Prac	tices (continued)		
*20. Are antimicrobial use and assurance/performance in	resistance data reviewed by nprovement committee meet		□ Yes □ No
consultant pharmacist tra		timicrobial stewardship expertise ship, stewardship team at referra ultant)?	
Electronic Health Record Ut	ilization		
*22. Indicate whether any of th	ne following are available in a	an <u>electronic health record</u> (chec	k all that apply):
☐ Microbiology lab cu susceptibility result	lture and antimicrobial S	\Box Medication orders	
\Box Medication adminis	tration record	\Box Resident vital signs	
□ Resident admission	notes	\Box Resident progress notes	
\Box Resident transfer o	r discharge notes	\Box None of the above	
Facility Water Management	and Monitoring Program		
spread in the facility water sys		-	
$\Box \le 1$ year ago		\Box >1 and \leq 3 years ago	
\square > 3 years ago			
24. Does your facility have a v transmission of <i>Legionella</i> and If Yes, who is represented		rne pathogens?	🗌 Yes 🗌 No
E Facility Administrator	□ Nursing Leadership (e.g., DON or ADON)	I I CONSULIANI	Facilities Manager/ Engineer
☐ Maintenance Staff	\Box Infection Preventionist	☐ Risk/Quality Management Staff	☐ Medical Director
Equipment/ Chemical	□ o	ther (specify):	
25. Do you regularly monitor th	ne following parameters in yo	our building's water system? (Ch	eck all that apply)
	uch as residual chlorine)	□ Yes □ No	
		ective actions when disinfectant	

Continued >>



NHSN National HealtParty 6 of 6	Long Term Care Facility Comp	onent—Anr	nual Facility	ty Survey			
	Temperature	🗌 Yes	🗆 No				
	If Yes, do you have a plan for correc temperatures are not within accepta your water management program?			□ Yes	□ No		
	Heterotrophic plate counts	🗌 Yes	🗌 No				
	If Yes, do you have a plan for corrective actions when heterotrophic plate counts are not within acceptable limits as determined by your water management program?		□ Yes	□ No			
	Specific tests for Legionella	🗌 Yes	🗆 No				
	If Yes, do you have a plan for correct tests for <i>Legionella</i> are not within ac by your water management program	ceptable limits as		□ Yes	□ No		